Free Trial
NASDAQ:INVA

Innoviva Q4 2024 Earnings Report

Innoviva logo
$18.72 +0.07 (+0.38%)
Closing price 05/2/2025 04:00 PM Eastern
Extended Trading
$18.72 0.00 (-0.03%)
As of 05/2/2025 05:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Innoviva EPS Results

Actual EPS
$0.57
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Innoviva Revenue Results

Actual Revenue
$91.81 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Innoviva Announcement Details

Quarter
Q4 2024
Time
After Market Closes
Conference Call Date
Wednesday, February 26, 2025
Conference Call Time
4:00PM ET

Upcoming Earnings

Innoviva's Q1 2025 earnings is scheduled for Tuesday, May 6, 2025, with a conference call scheduled on Wednesday, May 7, 2025 at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Innoviva Earnings Headlines

Warning: “DOGE Collapse” imminent
Elon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week, President Trump promised to buy a Tesla to help support Musk in the face of a boycott against his company. But according to one research group, with connections to the Pentagon and the U.S. government, Elon's preparing to strike back in a much bigger way in the days ahead.
See More Innoviva Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Innoviva? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Innoviva and other key companies, straight to your email.

About Innoviva

Innoviva (NASDAQ:INVA) engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.

View Innoviva Profile

More Earnings Resources from MarketBeat